The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market ...

Enter Mosun-Pola, which combines mosunetuzumab (Lunsumio), which is FDA-approved for patients with R/R follicular lymphoma after two or more lines of therapy, and polatuzumab vedotin (Polivy ...

The FDA has granted a priority review to Roche's T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December. The first-in-class drug ...

Lunsumio will provide an "off-the-shelf" alternative to CAR-T therapies like Gilead Sciences' Yescarta (axicabtagene ciloleucel) and Novartis' Kymriah (tisagenlecleucel), which have complex ...

Best International Companies to Own: 2025 Edition These companies from various corners of the globe are well positioned for the future.

Get the latest Roche Holding AG (RHHBY) stock news and headlines to help you in your trading and investing decisions.

Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key ...